Stroke Trial Analysis, Stem Cell Therapeutics Corp (TSX VENTURE: SSS)
June 25th, 2010
No comments
SSS reported that the top-line analysis for this clinical trial of NTx® 265 in acute stroke showed that there was substantial improvement in the primary efficacy endpoint Read more…
Categories: REGENESIS-Phase IIb stroke trial, Stem Cell Technology
